Abstracts tagged "Patient reported outcomes"

Abstract Number: 0143 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, Ken Hasegawa³, Thijs Hendrikx⁴, Annelies Boonen⁵, Bernard Combe⁶, David Walker⁷ and Rieke Alten⁸, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Maastricht University Medical Center, Maastricht, Netherlands, ⁶University of Montpellier, Montpellier, France, ⁷Northumbria Healthcare Trust, North Shields, United Kingdom, ⁸Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor currently being investigated as an agent to treat rheumatoid arthritis (RA). In the…
Abstract Number: 0186 • ACR Convergence 2020
The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
Magali Zanotti-Cavazzoni¹ and Gabriela Avila², ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Sociedad Paraguaya de Reumatologia, Asuncion, Paraguay
Background/Purpose: Disease activity scores (DAS) are used as tools to assess persistent inflammation and need for therapeutic escalation in patients with Rheumatoid arthritis (RA). One…
Abstract Number: 0356 • ACR Convergence 2020
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Laure Gossec¹, Philip Mease², Alice Gottlieb³, Deepak Assudani⁴, Jason Coarse⁵, Barbara Ink⁶ and Laura Coates⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Raleigh, NC, ⁶UCB Pharma, Slough, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes and…
Abstract Number: 0863 • ACR Convergence 2020
Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States
Diane Kamen¹, Julie Birt², Monica Hadi³, Nashmel Sargalo³, Ella Brookes³, Paul Swinburn³, Leslie Hanrahan⁴, Karin Tse⁵, Natalia Bello⁶, Kirstin Griffing², Maria Silk², Laure Delbecque⁷ and Anca Askanase⁸, ¹Medical University of South Carolina, Charleston, SC, ²Eli Lilly and Company, Indianapolis, IN, ³Evidera, London, United Kingdom, ⁴Carra Group, Milwaukee, WI, ⁵Lupus Foundation of America, DC, WA, ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Brussels, Belgium, ⁸Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Literature describes a fairly high degree of satisfaction with SLE therapies, despite patients reporting high rates of adverse event (1-2). The objectives of this…
Abstract Number: 1177 • ACR Convergence 2020
Rheumatic Diseases in Mexican Children and Their Psychosocial and Economic Impact on Caregivers
Fernando García Rodríguez¹, Brenda de Jesús Fortuna², Ingris Pelaez-Ballestas³, Enrique Faugier Fuentes⁴, Samara Mendieta Zerón⁵, Greta Reyes Cordero⁶, Sol Jiménez Hernández⁷, Ana Villarreal Treviño⁸, Jessica Guadarrama⁹, Sara Rosiles de la Garza⁸, Manuel de la O Cavazos⁸ and Nadina Rubio Pérez¹⁰, ¹Hospital Universitario "Dr. José E. González", Mexico City, Nuevo Leon, Mexico, ²Hospital Infantil De México Federico Gómez, Monterrey, Nuevo Leon, Mexico, ³Hospital General de Mexico, Mexico, Distrito Federal, Mexico, ⁴Hospital Infantil de México Federico Gómez, CDMX, Distrito Federal, Mexico, ⁵ISSEMYM Toluca, Estado de México, Distrito Federal, Mexico, ⁶Hospital Infantil de Especialidades de Chihuahua, Chihuahua, Chihuahua, Mexico, ⁷Hospital Universitario "Dr. José E. González", Monterrey, Mexico, ⁸Hospital Universitario "Dr.José E. González", Monterrey, Nuevo Leon, Mexico, ⁹Hospital Infantil de México Federico Gómez, CDMX, Distrito Federal, Mexico, ¹⁰Hospital Universitario "Dr. José E. González", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Pediatric rheumatic diseases (PRD) are a heterogeneous group of disorders. PRD patients and their caregivers face a number of challenges, these include the consequences…
Abstract Number: 1290 • ACR Convergence 2020
A Multitrait-Multimethod Matrix Approach to the Construct Validity of Patient Reported Outcomes Measurement Information System Computerized (PROMIS) Adaptive Tests (CAT) in Systemic Lupus Erythematous
Mitra Moazzami¹, Patricia Katz², Dennisse Bonilla³, Lisa Engel⁴, Jiandong Su⁵, Pooneh Akhavan⁶, Nicole Anderson⁵, Oshrat Tayer-Shifman⁷, Dorcas Beaton⁸ and Zahi Touma⁹, ¹George Washington University School of Medicine, Washington, DC, ²University of California, San Francisco, Novato, CA, ³University Health Network, Toronto, Canada, ⁴University of Manitoba, Toronto, ON, Canada, ⁵University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶Univesity of Toronto, Toronto, ON, Canada, ⁷Meir Medical Center, Raanana, Israel, ⁸Institue for Work and Health, Toronto, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada
Background/Purpose: Use of The Patient Reported Outcomes Measurement Information System computerized adaptive test (PROMIS-CAT) in adults with systemic lupus erythematous (SLE) is an emerging research…
Abstract Number: 1599 • ACR Convergence 2020
Workflows for Collecting and Using Patient-reported Outcomes Across Rheumatology Practices
Meera Subash¹, Kimberly DeQuattro², Sonam Choden³, Lucy Liu⁴, Puneet Bajaj⁵, Christie Bartels⁶, Jennifer Barton⁷, Bonnie Bermas⁸, Maria (Maio) Danila⁹, Julianna Desmarais¹⁰, Christina Downey¹¹, Sancia Ferguson¹², Sarah Goglin¹³, Margaret Guthrie¹⁴, Irum Jan¹⁵, Nikila Kumar¹⁶, Shraddha Prakash¹⁷, Kimberly Reiter¹⁸, Elizabeth Wahl¹⁹, Elena Weinstein²⁰, JoAnn Zell²¹, Gabriela Schmajuk²² and Jinoos Yazdany², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, San Francisco, ⁴Kaiser Permanente, Oakland, CA, ⁵UT Southwestern, Dallas, TX, ⁶University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ⁷VAPORHCS/OHSU, Portland, OR, ⁸UTSouthwestern.edu, Dallas, TX, ⁹University of Alabama at Birmingham (UAB), Birmingham, AL, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹Loma Linda University Medical Center, Redlands, CA, ¹²University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Oakland, CA, ¹³University of California San Francisco, Burlingame, CA, ¹⁴University of Alabama at Birmingham, DIv. of Clinical immunology & Rheum., Birmingham, AL, ¹⁵VA Albuquerque, Albuquerque, ¹⁶Arizona Arthritis & Rheumatology Associates, P.C., San Jose, CA, ¹⁷Oakcare Medical Group, Pleasanton, CA, ¹⁸Albuquerque VA Medical Center, Albuquerque, NM, ¹⁹VA Puget Sound Healthcare System, Seattle, WA, ²⁰University of Colorado, Englewood, CO, ²¹University of Colorado, Denver, CO, ²²University of California, San Francisco, Atherton, CA
Background/Purpose: The use of patient reported outcomes (PROs) during rheumatology visits may facilitate shared decision making and encourage patients to share their health goals. However,…
Abstract Number: 1866 • ACR Convergence 2020
Patient-reported Impact of Axial Spondyloarthritis on Working Life. Results from the Spanish Atlas 2017
Marco Garrido-Cumbrera¹, Eduardo Collantes-Estévez², Victoria Navarro-Compán³, Pedro Zarco⁴, Carlos Sastre⁵, Sergio Sanz-Gomez⁶, José Correa-Fernández⁷ and Jordi Gratacós⁸, ¹Health & Territory Research (HTR), Universidad de Sevilla / Spanish Federation of Spondyloarthritis Associations, Sevilla, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁴Novartis Farmacéutica Spain, Alcorcon, Madrid, Spain, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research, Seville, Spain, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Sevilla, Spain, ⁸University Hospital Parc Tauli Sabadell, Barcelona, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) impacts negatively on multiple dimensions of patient’s life, including their working life. The present study aims to evaluate working status, work-related…
Abstract Number: 0144 • ACR Convergence 2020
Age, Income, Education, and Health Conditions Are Associated with Patient Empowerment Among US Adults with Arthritis, but Race and Geography Are Not
Kathleen Carluzzo¹, Erin Knight-Zhang¹, Karen Schifferdecker¹, Emily Creek², Rebecca Butcher¹ and Guy Eakin², ¹Dartmouth College, Lebanon, NH, ²Arthritis Foundation, Atlanta, GA
Background/Purpose: The purpose of this study is to understand experiences of empowerment in healthcare visits among US adults with arthritis, and key factors associated with discrepancies…
Abstract Number: 0206 • ACR Convergence 2020
Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)
Naoto Tamura¹, Eiichi Tanaka², Eisuke Inoue³, Yuri Yoshizawa⁴, Shigeru Matsumoto⁵, Hisashi Yamanaka⁶ and Masayoshi Harigai⁷, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Bristol-Myers Squibb K.K., Tokyo, Japan, ⁵Ono Pharmaceutical Co., Ltd., Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Rheumatology, Sanno Medical Center, Tokyo, Japan, ⁷Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Long-term clinical benefit and patient-reported outcomes (PRO) of subcutaneously-injected abatacept (ABA) in patients with RA in a real-world setting are of therapeutic interest. We…
Abstract Number: 0358 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
Elke Riechers¹, Uta Kiltz², Jan Brandt-Jürgens³, Peter Kästner⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁴Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: There is growing body of evidence that smoking is associated with more active and severe disease in patients (pts) with ankylosing spondylitis (AS)1,2. The…
Abstract Number: 0873 • ACR Convergence 2020
Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Robert McLean², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Charlie Lovan⁵ and Alexis Ogdie⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., North Chicago, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of…
Abstract Number: 1201 • ACR Convergence 2020
Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials
Peter Taylor¹, Arthur Kavanaugh², Peter Nash³, Janet Pope⁴, Beatrix Bartok⁵, Ken Hasegawa⁵, Shangbang Rao⁵, Sander Strengholt⁶ and Rene Westhovens⁷, ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos BV, Leiden, Netherlands, ⁷University Hospitals Leuven, Belgium, Leuven, Belgium
Background/Purpose: RA patients (pts) often suffer substantial pain despite ongoing treatment (tx) and regard pain control as a top tx goal. Filgotinib (FIL)—a potent, oral…
Abstract Number: 1319 • ACR Convergence 2020
Disease Activity and Mental Health of as Patients: A Cross-section Study with Self-assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
Hui Song¹, Hua Wei², Miaojia Zhang³, Lijun Wu⁴, Zhenbiao Wu⁵, Aichun Chu⁶, Bei Wang⁷, Wenqiang Fan⁸, Xiaohan Wang⁹, Xiaoqi Chen¹⁰, Henglian Wu¹¹, Wenyu Zhou¹², Fei Xiao¹³, Hui Xiao¹⁴, Yuhua Jia¹³, Bing Wu¹³ and Jing Lu¹⁵, ¹Beijing Jishuitan Hospital, Beijing, China (People's Republic), ²Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ³Jiangsu Province Hospital, The first affiliated hospital of Nanjing medical university, Nanjing, China (People's Republic), ⁴People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), ⁵The First Affiliated Hospital of The Air Force Medical University, Xi＇an, Shanxi, China (People's Republic), ⁶Remin Hospital of Wuhan University Hubei General Hospital, Wuhan, China (People's Republic), ⁷Beijing Hospital of Traditional Chinese Medicine, Beijing, China (People's Republic), ⁸Central Hospital of XinXiang, Xinxiang, China (People's Republic), ⁹Anyang district hospital, Anyang, Henan, China (People's Republic), ¹⁰Zhongnan Hospital of Wuhan University, Wuhan, China (People's Republic), ¹¹Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), ¹²Wuhan No. 4 Hospital, Wuhan, China (People's Republic), ¹³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁵First Affiliated Hospital of China Medical University, Shenyang, China (People's Republic)
Background/Purpose: WHO survey showed that the prevalence of anxiety and depression in Chinese population and Chinese patients with chronic diseases were between 3.1% - 4.2%…
Abstract Number: 1600 • ACR Convergence 2020
Relationship Between Electronic Health Record Vendor and Performance on Patient-reported Outcome Quality Measures in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Nevin Hammam¹, Gabriela Schmajuk², Jing Li³, Michael Evans¹, Julia Kay¹ and Jinoos Yazdany³, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, Atherton, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: Routine collection of disease activity and patient reported outcomes (PROs) such as functional status assessment in rheumatoid arthritis (RA) are nationally endorsed quality measures…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].